Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NitroMed’s BiDil XR Will Use Elan Delivery Technology Under Recent Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

Collaboration centers on use of Elan’s proprietary oral controlled-release delivery technology.

You may also be interested in...



NitroMed Looks To 2010 NDA For BiDil XR

Firm decides to slash jobs, quit promotion of immediate-release BiDil to fund development and commercialization of extended-release version.

NitroMed Looks To 2010 NDA For BiDil XR

Firm decides to slash jobs, quit promotion of immediate-release BiDil to fund development and commercialization of extended-release version.

NitroMed's BiDil Approved For Heart Failure In Self-Identified Black Patients

The hydralazine/isosorbide dinitrate combination is the first approval for a race-based indication. In its recent review of BiDil, an FDA advisory committee suggested race was serving as a surrogate for genomic markers. FDA suggests further study could expand BiDil's approval beyond self-identified black patients.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel